Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 562

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia

Pei, Shanshan, Pollyea, Daniel A., Gustafson, Annika, Stevens, Brett M., Minhajuddin, Mohammad, Fu, Rui, Riemondy, Kent A., Gillen, Austin E., Sheridan, Ryan M., Kim, Jihye, Costello, James C., Amaya, Maria L., Inguva, Anagha, Winters, Amanda, Ye, Haobin, Krug, Anna, Jones, Courtney L., Adane, Biniam, Khan, Nabilah, Ponder, Jessica, Schowinsky, Jeffrey, Abbott, Diana, Hammes, Andrew, Myers, Jason R., Ashton, John M., Nemkov, Travis, D'Alessandro, Angelo, Gutman, Jonathan A., Ramsey, Haley E., Savona, Michael R., Smith, Clayton A., Jordan, Craig T.·2020·Cancer Discovery

Abstract

Venetoclax-based therapy can induce responses in approximately 70% of older previously untreated patients with acute myeloid leukemia (AML). However, up-front resistance as well as relapse following initial response demonstrates the need for a deeper understanding of resistance mechanisms. In the present study, we report that responses to venetoclax +azacitidine in patients with AML correlate closely with developmental stage, where phenotypically primitive AML is sensitive, but monocytic AML is more resistant. Mechanistically, resistant monocytic AML has a distinct transcriptomic profile, loses expression of venetoclax target BCL2, and relies on MCL1 to mediate oxidative phosphorylation and survival. This differential sensitivity drives a selective process in patients which favors the outgrowth of monocytic subpopulations at relapse. Based on these findings, we conclude that resistance to venetoclax + azacitidine can arise due to biological properties intrinsic to monocytic differentiation. We propose that optimal AML therapies should be designed so as to independently target AML subclones that may arise at differing stages of pathogenesis. Significance: Identifying characteristics of patients who respond poorly to venetoclax-based therapy and devising alternative therapeutic strategies for such patients are important topics in AML. We show that venetoclax resistance can arise due to intrinsic molecular/metabolic properties of monocytic AML cells and that such properties can potentially be targeted with alternative strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-19-0710

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 562

Metadata

Authors
Pei, S., Pollyea, D. A., Gustafson, A., Stevens, B. M., Minhajuddin, M., Fu, R., Riemondy, K. A., Gillen, A. E., Sheridan, R. M., Kim, J., Costello, J. C., Amaya, M. L., Inguva, A., Winters, A., Ye, H., Krug, A., Jones, C. L., Adane, B., Khan, N., Ponder, J., Schowinsky, J., Abbott, D., Hammes, A., Myers, J. R., Ashton, J. M., Nemkov, T., D'Alessandro, A., Gutman, J. A., Ramsey, H. E., Savona, M. R., Smith, C. A., & Jordan, C. T.
Venue
Cancer Discovery
Published
2020-04-01
Volume
10
Issue
4
Pages
536-551
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W3001120382
Cited by
562
References
48
FWCI
34.43
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. https://app.cochat.ai/papers/10.1158/2159-8290.cd-19-0710
The paper
Pei, S., Pollyea, D. A., Gustafson, A., Stevens, B. M., Minhajuddin, M., Fu, R., Riemondy, K. A., Gillen, A. E., Sheridan, R. M., Kim, J., Costello, J. C., Amaya, M. L., Inguva, A., Winters, A., Ye, H., Krug, A., Jones, C. L., Adane, B., Khan, N., . . . Jordan, C. T. (2020). Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-19-0710

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.